BACKGROUND: Individuals infected with human immunodeficiency virus (HIV) who have previously had syphilis may have cognitive impairment. We tested the hypothesis that neurosyphilis causes cognitive impairment in HIV by amplifying HIV-related central nervous system (CNS) inflammation. METHODS: HIV-infected participants enrolled in a study of cerebrospinal fluid (CSF) abnormalities in syphilis underwent the mental alternation test (MAT), venipuncture, and lumbar puncture. CSF concentrations of chemokine (C-X-C motif) ligand 10 (CXCL10), chemokine (C-C motif) ligand 2 (CCL2), and neurofilament light (NFL) were determined by commercial assays. The proportion of peripheral blood mononuclear cells (PBMCs) and of CSF white blood cells (WBCs) that were activated monocytes (CD14+CD16+) was determined by flow cytometry. Neurosyphilis was defined as detection of Treponema pallidum 16S RNA in CSF or CSF white blood cells (WBCs) >20/uL or a reactive CSF-Venereal Disease Research Laboratory (VDRL) test; uncomplicated syphilis was defined as undetectable CSF T. pallidum, CSF WBCs ≤5/uL and nonreactive CSF-VDRL. MAT <18 was considered low. RESULTS: Median proportion of PBMCs that were activated monocytes (16.6 vs. 5.3), and median CSF CXCL10 (10658 vs. 2530 units), CCL2 (519 vs. 337 units) and HIV RNA (727 vs. 50 c/mL) were higher in neurosyphilis than in uncomplicated syphilis (P ≤ .001 for all comparisons). Neurosyphilis was not related to low MAT scores. Participants with low MAT scores had higher median CSF CXCL10 (10299 vs. 3650 units, P = .008) and CCL2 (519 vs. 365 units, P = .04) concentrations than those with high MAT scores. CONCLUSIONS: Neurosyphilis may augment HIV-associated CNS inflammation, but it does not explain cognitive impairment in HIV-infected individuals with syphilis.
BACKGROUND: Individuals infected with human immunodeficiency virus (HIV) who have previously had syphilis may have cognitive impairment. We tested the hypothesis that neurosyphilis causes cognitive impairment in HIV by amplifying HIV-related central nervous system (CNS) inflammation. METHODS: HIV-infected participants enrolled in a study of cerebrospinal fluid (CSF) abnormalities in syphilis underwent the mental alternation test (MAT), venipuncture, and lumbar puncture. CSF concentrations of chemokine (C-X-C motif) ligand 10 (CXCL10), chemokine (C-C motif) ligand 2 (CCL2), and neurofilament light (NFL) were determined by commercial assays. The proportion of peripheral blood mononuclear cells (PBMCs) and of CSF white blood cells (WBCs) that were activated monocytes (CD14+CD16+) was determined by flow cytometry. Neurosyphilis was defined as detection of Treponema pallidum 16S RNA in CSF or CSF white blood cells (WBCs) >20/uL or a reactive CSF-Venereal Disease Research Laboratory (VDRL) test; uncomplicated syphilis was defined as undetectable CSF T. pallidum, CSF WBCs ≤5/uL and nonreactive CSF-VDRL. MAT <18 was considered low. RESULTS: Median proportion of PBMCs that were activated monocytes (16.6 vs. 5.3), and median CSF CXCL10 (10658 vs. 2530 units), CCL2 (519 vs. 337 units) and HIV RNA (727 vs. 50 c/mL) were higher in neurosyphilis than in uncomplicated syphilis (P ≤ .001 for all comparisons). Neurosyphilis was not related to low MAT scores. Participants with low MAT scores had higher median CSF CXCL10 (10299 vs. 3650 units, P = .008) and CCL2 (519 vs. 365 units, P = .04) concentrations than those with high MAT scores. CONCLUSIONS: Neurosyphilis may augment HIV-associated CNS inflammation, but it does not explain cognitive impairment in HIV-infected individuals with syphilis.
Authors: Katrien Van Raemdonck; Philippe E Van den Steen; Sandra Liekens; Jo Van Damme; Sofie Struyf Journal: Cytokine Growth Factor Rev Date: 2014-11-22 Impact factor: 7.638
Authors: Ajay R Bharti; Allen McCutchan; Reena Deutsch; Davey M Smith; Ronald J Ellis; Mariana Cherner; Steven P Woods; Robert K Heaton; Igor Grant; Scott L Letendre Journal: Clin Infect Dis Date: 2016-10-28 Impact factor: 9.079
Authors: Sergio Monteiro de Almeida; Archana Bhatt; Patricia K Riggs; Janis Durelle; Deborah Lazzaretto; Jennifer Marquie-Beck; Allen McCutchan; Scott Letendre; Ronald Ellis Journal: J Neurovirol Date: 2010-02 Impact factor: 2.643
Authors: Christina M Marra; Clare L Maxwell; Stacy L Smith; Sheila A Lukehart; Anne M Rompalo; Molly Eaton; Bradley P Stoner; Michael Augenbraun; David E Barker; James J Corbett; Mark Zajackowski; Charles Raines; Judith Nerad; Romina Kee; Scott H Barnett Journal: J Infect Dis Date: 2004-01-27 Impact factor: 5.226
Authors: C M Marra; R Deutsch; A C Collier; S Morgello; S Letendre; D Clifford; B Gelman; J McArthur; J A McCutchan; D M Simpson; N A Duarte; R K Heaton; I Grant Journal: Int J STD AIDS Date: 2013-06-14 Impact factor: 1.359
Authors: M Métral; Kea Darling; I Locatelli; I Nadin; G Santos; P Brugger; H Kovari; A Cusini; K Gutbrod; P E Tarr; A Calmy; T D Lecompte; F Assal; A Monsch; U Kunze; M Stoeckle; M Schwind; P Schmid; R Pignatti; C Di Benedetto; R Du Pasquier; M Cavassini Journal: HIV Med Date: 2019-10-07 Impact factor: 3.180
Authors: Monica M Diaz; Marcela Gil Zacarías; Patricia Sotolongo; María F Sanes; Donald J Franklin; María J Marquine; Mariana Cherner; Cesar Cárcamo; Ronald J Ellis; Serggio Lanata; Patricia J García Journal: Front Neurol Date: 2021-06-17 Impact factor: 4.086